WIDE FIT KRUPA Espadrilles black Best Seller Cheap Price xxvrjWW5

WIDE FIT KRUPA - Espadrilles - black Best Seller Cheap Price xxvrjWW5
WIDE FIT KRUPA - Espadrilles - black
Compare( 0 )
1 (866) 444-4955 Cheap Sale Choice High heeled sandals mirror rose Buy Cheap 2018 Unisex Prices Cheap Online U5Z62m
Contact methods
ONLBOBBY SHINY Classic ankle boots black Discount Low Shipping Fee Cheap Sale Visit Cheap Sale With Mastercard iQ9t5
Advanced Search
Specialty Searches
Stuart Weitzman Bow PeepToe Pumps w/ Tags Looking For Cheap Sale Extremely f6g3bw9EZU
Clearance 100% Guaranteed Best Wholesale Cheap Online Brunello Cucinelli Metallic LowTop Sneakers Explore Cheap Online Clearance Best Wholesale bwthgFn
About Us
Best Wholesale Cheap Price Ebay Cheap Online Sarah Jessica Parker Pointed Bow Pumps Outlet Discount Sale 1Cc0ed

There was a time when the words “budget” and “Android” conjured images of disposable, plastic phones with small screens.

The Moto G5 Plus punches way above its weight with a quality 5.2-inch 1080p display, metal body, fingerprint sensor, and a very decent camera for its price. For $230 you get 32GB of storage and 2GB of RAM with a Snapdragon 625 processor, or for $300 you can bump that up to 4GB of RAM and 64GB of storage.It’s also fully 4G LTE compatible on all four major U.S. carriers—something that few budget phones can claim.

The phone has its drawbacks, including a lack of NFC. Also, the camera is just adequate—it doesn’t hold up against top-end phones.

As a complete package, though, the build quality, specs, performance, battery life, and software experience here is way better than what we’re used to seeing in the $200-$300 price range.

$269.00 MSRP $269.00
Shop Coach Karessa Thong Sandals View Supply Sale Online Z2mUgQ7s

While the Moto G5 Plus offers a fantastic near-stock Android skin, there’s no guarantee that you’ll be getting updates this time next year. With the Nokia 6.1 you will, and that makes it a budget phone well worth considering.

The specs of the 5.5-inchNokia 6.1 are fairly average for a phone in this price point:Snapdragon 630 processor, 4GB of RAM, 3,000mAh battery, and a16 MP f/2.0 main camera, However, Nokia offers something its competitors don’t: Android One. That means you’re getting a near-stock version of Android, without a single extra app or UI tweak, plus a guarantee of three years of security updates and two years of version upgrades. That’s Android P and Android Q, a promise other phones in this price range simply can’t deliver.

While Nokia doesn’t make any guarantees on the speed of the updates, Android One means the company works directly with Google to ensure they’re delivered in a timely manner. And they’ll definitely arrive quicker than with other phones in this range. For example, the Moto G5 Plus is still waiting for its Oreo update, nearly 10 months after it released.

Unfortunately the usual GSM caveats apply here, so Verizon and Sprint customers are out of luck. But ATT and T-Mobile subscribers looking for the pure Android experience should give Nokia a long, hard look.

Read Greenbot's review
Outlet Authentic Buy Cheap Reliable Carla 10 sneakers Cheap Low Cost Clearance Sale QHGTK2ux
MSRP $529.00
on OnePlus.com

The OnePlus 6 has stepped up its design game in a big way, bringing an all-glass back, killer display, and premium specs, all while keeping its low price.

NYTimes.com no longer supports Internet Explorer 9 or earlier. Please upgrade your browser. LEARN MORE »
Ankle boots cathay nuit Shop For Very Cheap Fast Delivery Online 4CDRN9f
Skip to navigation View mobile version

Malone Souliers Bicolor LaceUp Pumps For Sale Discount Sale Discount Low Shipping Fee Cheap Sale Official Site Free Shipping Get To Buy A41uk

Magazine | The Trivialities and Transcendence of Kickstarter


Supported by


Continue reading the main story

We had this idea, some friends and I, for a small public art project in New Orleans last year. The problem was, it involved some professional printing that would cost a few thousand dollars, which none of us had. Usually that’s where such conversations end: it would be cool if we could do X, but we’re not going to get a grant from the National Endowment for the Arts, even if we knew how to pursue such a thing. So let’s get another round of beers.

But this time something occurred to me: What about that Kickstarter thing? Kickstarter has been around online for just over two years, and various artists, filmmakers, musicians, writers and designers have used the site to raise more than $75 million for 10,626 “creative projects,” to use Kickstarter’s preferred term. That money has come from 813,205 “backers” — individuals making mostly modest contributions (the most common is $25) to support specific efforts. The selling point of “crowd-funding,” as this phenomenon has come to be called, is that it is an alternative to the wealthy patron or the grant-giving foundation. Kickstarter has become the most talked-about example of this democratizing technology: an arts organization for the post-gatekeeper era.

To see the full article, subscribe here.




The best of The New York Times Magazine delivered to your inbox every week, including exclusive feature stories, photography, columns and more.

Thank you for subscribing.

An error has occurred. Please try again later.

You are already subscribed to this email.

View all New York Times newsletters.


Rob Walker ([email protected]) is a contributing writer for the magazine and a contributor to Design Observer.

Editor: Vera Titunik ([email protected])

A version of this article appears in print on August 7, 2011, on Page MM32 of the Sunday Magazine with the headline: Dream Machine. Today's Paper | Subscribe

Gold Open Access is provided by OA Publishing London read more

For citation purposes: Power BD, Looi JCL. The thalamus as a putative biomarker in neuropsychiatry. OA Neurosciences 2014 Mar 21;2(1):6.
B Power , J Looi

Authors affiliations

(1) School of Medicine Fremantle, The University of Notre Dame Australia, Fremantle Australia

(2) Clinical Research Centre, North Metropolitan Health Service - Mental Health, Perth Australia

(3) Research Centre for the Neurosciences of Ageing, Academic Unit of Psychiatry and Addiction Medicine, Australian National University Medical School, Canberra Hospital, Canberra, Australia

* Corresponding author Email:



With a strategic central location between other subcortical structures and cortex, the thalamus is a pivotal hub in the subcortical connectome. Whilst the precise function of the thalamus is unclear, there is a growing body of literature unravelling its functional connectivity and potential involvement in a plethora of neuropsychiatric disorders. This article provides a brief overview of its functional neuroanatomy focusing on the dorsal thalamus, before presenting an overview of neuroimaging findings of thalamic morphology in a range of disorders, from schizophrenia and obsessive compulsive disorder, to various neurodegenerative disorders, such as Alzheimer’s dementia and progressive supranuclear palsy.


Mapping thalamic morphology in various neuropsychiatric disorders may provide important information regarding the onset, progression and, when disease-modifying agents are available, response to treatment.



During development the primitive forebrain gives rise to the telencephalon (or end-brain, from which arise the cerebral cortex, striatum, amygdala, and associated structures) and the diencephalon (or between-brain, which gives rise to the thalamus and hypothalamus). Maturation of the thalamus and cortex are closely linked, such that a thalamic abnormality in the early neurodevelopmental period may impair normal cortical development (and vice versa) and, not surprisingly, thalamic pathology has been implicated in the neurobiology of schizophrenia. The neurodevelopment of the thalamus has been summarized extensively, and significant genetic factors have been identified. Further studies will be needed to ascertain whether genetic factors are associated with thalamic morphology, and hence provide the basis for putative endophenotypes in neuropsychiatric disorders.

The thalamus (from the Greek word thalamos, used to refer to an inner-most room, storeroom, or bridal chamber) can be divided into dorsal and ventral divisions: the dorsal thalamus is composed of nuclei having reciprocal connections with the cerebral cortex and striatum, whereas the ventral thalamus does not generally project to the cortex. In humans, the dorsal thalamus is a paired structure, with a strategic central location between other subcortical structures and cortex. The two distinct dorsal thalami are located at the base of each cerebral hemisphere on either side of the third ventricle respectively (see Figure 1 ). The dorsal thalamus has anterior, medial and lateral subdivisions, defined by a curved sheet of myelinated fibres called the internal medullary lamina. These subdivisions are composed of distinct thalamic nuclei, based on cytoarchitecture, patterns of connectivity and functionality (see Table 1 ), however these nuclei share many features as outlined below.

There are two types of neurons in dorsal thalamic nuclei which can be distinguished by their morphology and chemoarchitecture: locally acting GABAergic interneurons and glutamatergic relay cells projecting outside of the thalamus. The physiological properties of thalamic relay neurons indicate that they can undergo two main types of response modes which will determine the nature of the message relayed to the cortex: a burst response mode is thought to be utilized for signal detection, whereas a tonic response mode is believed to be utilized by the thalamic relay cells for more accurate signal analysis. It has been suggested that disruption of modulatory processes (i.e., shifting from signal analysis to signal detection) may lead to aberrant salience, such as that seen in schizophrenia.

The nuclei of the dorsal thalamus can be considered to receive two types of afferent fibres which are classified as either drivers or modulators, regardless of their origin (i.e., cortical or subcortical), and which can be defined on the basis of their synaptic morphology and post synaptic actions. In this sense, the drivers are essentially those afferents to the thalamus that carry the message to be passed on by the thalamocortical cells, whereas the modulators are those afferents to the thalamus that influence how this message is passed on by those thalamocortical cells.

Thalamic nuclei can be classified according to the afferents they receive. First order (or primary,) nuclei receive their drivers from a peripheral or subcortical structure, and receive modulators from pyramidal cells in layer VI of the ipsilateral cortex. In this scheme, visual, somatosensory and auditory afferents send peripheral sensory information to first order nuclei of the thalamus.

On the other hand, higher order (or association) nuclei receive their drivers from pyramidal cells in layer V of the ipsilateral cortex. In this scheme, higher order relays pass messages from one cortical area to another, regarding current output to motor or premotor centres from the driving cortical area, for instance. Just as sensory information passes through first order nuclei en route to cortex, so too corticocortical information passes through higher order nuclei (with direct corticocortical pathways providing some other function e.g., modulatory); this challenges the conventional view of corticocortical transmission. With regard to response mode of relay cells in higher order nuclei, it is thought that burst and tonic modes are utilized in a similar fashion: burst mode may be engaged to indicate a shift in the pattern of output in transthalamic corticocortical communication (from one cortical area to the other), and tonic mode then engaged by the higher order relay cells to transfer information more reliably to the other cortical area. Of note, research suggests there is more bursting in higher order nuclei than in first order relays. Although limited, current evidence suggests that drivers to higher order relays come from several different cortical areas, suggesting the relay is likely to represent several different functions. Whilst their precise function remains elusive, what is clear from the study of the higher order nuclei is that at least half of the thalamus is dedicated to transthalamic corticocortical communication, with the implication that disruption of this type of signaling could impact on higher cortical functions.

Indeed, the role of the thalamus in perceptual processing is likely to be significant: Sherman and Guillery speculate that a function of thalamocortical inputs to cortex (either first order or higher order) could be to keep the cortex updated on the most recent motor commands.

Many of the afferent and efferent connections of the thalamus are mapped, including driver afferents to first order nuclei, as well as topographically organized first and higher order thalamocortical and corticothalamic pathways. Trans-synaptic neurodegeneration has been proposed as a mechanism in neurodegenerative disease whereby deafferentation from cortical neurons can lead to synaptic dysfunction and hence neuronal spread of disease along vulnerable neural networks. This could be one mechanism that leads to subcortical pathology such as neuronal loss in neurodegenerative disease, as evidenced in the striatum in Huntington’s disease (HD), frontotemporal dementia (FTD) and Alzheimer’s disease (AD). Given the topographical relationship of thalamus to cortex, one would predict that the thalamus could serve as a map of structural change in the cortical afferent pathways in various neurodegenerative conditions.

From a neural circuit perspective, there are a number of well-defined anatomical loops involving the thalamus in addition to those already described. For instance, fronto-striatal-thalamocortical circuits are thought to form the main network by which motor activity and behaviour in humans is mediated, and may explain the similarity of behavioural changes in frontal cortical and subcortical disorders. The thalamus is a critical hub in these networks. It is proposed that cortico-subcortical lesions in neurodegenerative disease processes may disconnect these circuits, and this underpins the manifest neuropsychiatric dysfunction, such as cognitive and behavioural disturbances seen in FTLD for instance. Similarly, dysfunction of cerebellothalamocortical pathways have also been linked to neuropsychiatric disease. Andreasen and colleagues have reported that disruption of neural circuits linking the cortex, thalamus and cerebellum may be at play in schizophrenia, speculating that disruption of this circuitry may underpin emotional and cognitive dysfunction. As a pivotal structure in the subcortical connectome, further investigation of the thalamus is likely to be fruitful in various neuropsychiatric disorders.

Thalamic function and dysfunction

With the exclusive exception of most olfactory inputs, all sensory pathways on route to the cerebral cortex first pass through the dorsal thalamus. It was thought that the function of the dorsal thalamus extended no further than relaying information, and indeed it has been described as the “gateway” to the cortex. In terms of a current conceptualization of thalamic function, the thalamic relay is thought to function as a modulatory gate (rather than an integrator of a number of messages) with its component relay cells passing the message from their driving afferent (be it cortical or subcortical) to the cortex; signalling occurs either in burst or tonic modes, albeit with slight modifications. Whilst it is not entirely clear what advantage is subserved by sending information through the thalamus before it reaches a cortical area, this will be pivotal in understanding the thalamus. In conceptualizing the role of the thalamus in neuropsychiatric disorders, it will be useful to consider a failure of neural circuitry involving the thalamus, rather than neuropsychiatric symptoms arising directly from the thalamus itself. The role of thalamic pathology in the disease state could then be considered a failure of its relay functions or an abnormality of gating that acts on the messages it receives. The aim of this critical review was to discuss the thalamus as a putative biomarker in neuropsychiatry.


The authors have referenced some of their own studies in this review. These referenced studies have been conducted in accordance with the Declaration of Helsinki (1964) and the protocols of these studies have been approved by the relevant ethics committees related to the institution in which they were performed. All human subjects, in these referenced studies, gave informed consent to participate in these studies.


The following section offers a concise overview of some of the findings of thalamic morphology using structural MRI in a range of psychotic, mood and anxiety disorders; given the constraints of space, data pertaining to functional MRI and diffusion tensor imaging (DTI) in these disorders is beyond the scope of this overview.

A comprehensive review of thalamic anomalies in schizophrenia has been provided by Byne and colleagues. A meta-analysis by Konick and Friedman suggests a volume deficit of the thalamus relative to brain size in schizophrenia, and thalamic size has been demonstrated to correlate inversely with symptom severity. Thalamic volume deficit has been reported in first-episode psychosis, medication-naïve patients with schizophrenia, as well as those patients who were taking antipsychotic medication, and there is conflicting data regarding whether thalamic volume increases with antipsychotic medications. The majority of thalamic volume deficit in schizophrenia involves primarily two thalamic nuclei, namely the medial dorsal thalamic nucleus (MD) and the pulvinar, which relate to prefrontal and temporal cortices. The medial dorsal nucleus (its efferent fibres targeting the prefrontal cortex in a topographical manner) has received particular attention in schizophrenia, with consistent reports of bilateral volume reduction in MD relative to healthy controls; similarly bilateral volume deficits have been reported in the pulvinar. An MRI study in 46 individuals with early-onset psychosis and 34 healthy controls supported these findings, and revealed a regional reduction in thalamic volumes between groups (most significant in the right anterior MD area and pulvinar). Gaser and colleagues argue that thalamic shrinkage (in the regions corresponding to MD and the pulvinar) appears to be an important determinant of ventriculomegaly in patients with schizophrenia, rather than diffuse brain atrophy.

Disparate findings regarding thalamic morphology have been reported in mood disorders, with a ‘mega-analysis’ of 321 patients with bipolar affective disorder (type 1) reporting no variation in thalamic volumes compared with controls, and a meta-analysis of 20 voxel-based morphometry studies in major depressive disorder involving 543 patients and 750 controls supporting reduced thalamic volumes in patients with depression. Thalamic volume has been reported as increased bilaterally in medication-naïve patients with obsessive compulsive disorder (OCD) in child and adult populations, and a reduction in thalamic volume reported following antidepressant treatment. There is sparse information of thalamic morphology in other anxiety disorders, which may in part reflect the very distinctive morphological findings in OCD compared with other anxiety disorders as reported in a recent meta-analysis.

Whilst structural MRI in psychiatric conditions has limited clinical utility at the present time, for the time being it continues to yield important information that enhances our etiological understanding of disease from a brain structural basis.


The majority of neuroimaging studies in the common neurodegenerative disorders have focused on dysfunctional neocortical networks in the common neurodegenerative disorders, most likely because of the crucial roles of neocortex in higher cortical functions. There is a growing body of literature identifying the role of important subcortical structures in these networks, such as the striatum in AD, behavioural variant FTD, progressive nonfluent aphasia and stroke. Relatively few studies have investigated thalamic morphology in the neurodegenerative disorders.

In familial AD, thalamic atrophy has been reported in the pre-symptomatic stage of disease, and thalamic atrophy has been reported in sporadic AD relative to controls. Further, thalamic atrophy in AD is associated independently with cognitive deterioration, controlling for age, gender, educational level, intracranial volume and neocortical grey matter volume. Longitudinal studies of thalamic morphology in AD are warranted.

Thalamic atrophy on MRI has been reported in cohorts with progressive supranuclear palsy (PSP) relative to controls, but not in patients with Parkinson’s disease (PD), multisystem atrophy, cortico-basal degeneration (CBD), or dementia with Lewy bodies (DLB). In a multi-modal approach, Whitwell and colleagues reported atrophy in the thalamus in PSP using MRI and reduced thalamic functional connectivity using fMRI relative to controls, with DTI data implicating the ventrolateral (or motor) thalamus. Using DTI and structural MRI, thalamic atrophy has been reported early in the disease stages of PSP primarily affecting the pulvinar, medial dorsal and anterior nuclei, and using serial MRIs at 6 month intervals, progressive thalamic atrophy over time relative to controls has also been reported. The morphology of the thalamus might thus be a useful biomarker in PSP.

Significant atrophy has been reported in the thalamus of patients with FTD compared with controls, however it is yet to be determined how thalamic morphology relates to the specific pathological subtypes of this heterogeneous condition, and this requires further investigation. Thalamic atrophy has been associated with cognitive deterioration (but not other clinical features, such as motor function) in early stages of HD relative to controls; symmetrical atrophy in the regions of the medial dorsal nucleus, and the ventral lateral and intralaminar nuclear groups were reported. Further investigation of thalamic morphology is warranted in HD, together with longitudinal data if indicated.


Further studies are required to investigate how the morphology (shape and volume) of the thalamus is relevant to and indicative of the integrity of neural circuits subserving cognition, emotion, movement and behaviour. From a clinical perspective, correlation of these clinical features (e.g., cognitive or emotional disturbance, or movement disorder) with thalamic morphology will provide a better understanding of the neurobiology of neuropsychiatric conditions, and potentially yield clinically useful biomarkers. Further, determining whether genetic factors are associated with thalamic volume may provide a genetic basis for an endomorphotype, and hence provide putative endophenotypes in neuropsychiatric disorders.

Whilst the significance of altered thalamic morphology in schizophrenia, depressive disorders and OCD is yet to be determined, further studies are warranted. For instance, investigating for an association between thalamic atrophy and cognitive dysfunction in schizophrenia may be fruitful, particularly in patients enrolled in genome wide association studies. Whilst structural MRI in these conditions has limited clinical utility at the present time, it has the potential to advance our etiological understanding of psychiatric disease from a brain structural basis.

Preliminary data in the neurodegenerative disorders suggests that investigating thalamic morphology is likely to yield biomarkers for these disorders. Most age-related neurodegenerative disorders are characterized not only by abnormal folding and accumulation of disease-specific proteins, but also progressive pathological changes that occur in anatomical patterns that are characteristic of a particular dementia (which likely underpins the characteristic clinical syndromes for different dementias). The conceptualization of the dementias on a neural circuit basis suggests that these abnormal proteins take seed in a particular part of the nervous system and then migrate along the brain’s intrinsic pathways over time, affecting through a plethora of mechanisms both cortical and subcortical structures. Hence, as a pivotal structure in the subcortical connectome, it is not surprising that altered thalamic morphology has been identified in AD, PSP and FTD, and possibly HD.


Mapping thalamic morphology in neuropsychiatric disease may provide important information regarding the onset, progression and ultimately (when disease-modifying agents are available), treatment response in a form directly related to neuropsychiatric dysfunction.


The authors funded research and infrastructure costs via their respective centres.

Conflict of interests

None declared.

Competing interests

None declared


1.Byne W, Hazlett EA, Buchsbaum MS, Kemether E. The thalamus and schizophrenia: current status of research. Acta Neuropathologica. 2009; 117: 347-68.

2.Jones EG. The Thalamus. 2nd edition. Cambridge: Cambridge University Press; 2007.

3.Blackshaw S, Scholpp S, Placzek M, Ingraham H, Simerly R, Shimogori T. Molecular pathways controlling development of thalamus and hypothalamus: from neural specification to circuit formation. The Journal of Neuroscience. 2010; 30: 14925-30.

4.Sherman SM, Guillery RW. Exploring the thalamus and its role in cortical function. 2nd edition. Cambridge: MIT Press; 2006.

5.Ramcharan EJ, Gnadt JW, Sherman SM. Higher order thalamic relays burst more than do first order relays. Proceedings of the National Academy of Sciences of the USA. 2005; 102: 12236-41.

6.Guillery RW, Feig SL, Van Lieshout DP. Connections of higher order visual relays in the thalamus: a study of corticothalamic pathways in cats. Journal of Comparative Neurology. 2001; 43; 66-85.

7.Guillery RW. Anatomical evidence concerning the role of the thalamus in corticocortical communication: a brief review. Journal of Anatomy. 1995; 187: 583-92.

8.Palop JJ, Mucke L. Synaptic depression and aberrent excitatory network activity and Alzheimer’s disease: two faces of the same coin? Neuromolecular Medicine. 2009; 12: 48-55.

9.Looi JCL, Walterfang M. Striatal morphology as a biomarker in neurodegenerative disease. Molecular Psychiatry. 2012; 18: 417-24.

10.Looi JCL, Walterfang M, Velakoulis D, Macfarlane MD, Svensson L, Wahlund LO. Frontotemporal Dementia as a frontostriatal disorder: neostriatal morphology as a biomarker and structural basis for an endophenotype. Australian and New Zealand Journal of Psychiatry. 2012; 46: 422-34.

11.Alexander GE, DeLong MR, Strick PL. Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annual Reviews of Neuroscience. 1986; 9: 357-81.

12.Haber S, Calzavara R. The cortico-basal ganglia integrative network: The role of the thalamus. Brain Research Bulletin. 2009; 78: 69-74.

13.Andreasen NC, Pearson R. The role fo the cerebellum in schizophrenia. Biological Psychiatry. 2008; 64: 81-8.

14.Looi JCL, Walterfang M, Nilsson C, Power BD, van Westen D, Velakoulis D, Wahlund LO, Thompson PM. The subcortical connectome: hubs, spokes and the space between. Australian and New Zealand Journal of Psychiatry. 2013; DOI: 10.1177/0004867413506753.

15.Konick LC, Friedman L. Meta-analysis of thalamic size in schizophrenia. Biological Psychiatry. 2001: 49: 178-86.

16.Crespo-Facorro B, Roiz-Santianez R, Pelayo-Teran JM, Rodriguez-Sanchez JM, Perez-Iglesias R, Gonzalez-Blanch C, Tordesillas-Gutierrez D, Gonzalez-mandly A, Diez C, Magnotta VA, Andreasen NC, Vazquez-Barquero JL. Reduced thalamic volume in first-episode non-affective psychosis: correlations with clinical variables, symptomatology and cognitive functioning. Neuroimage. 2007; 35(4): 1613-23.

17.Adriano F, Spoletini I, Caltagirone C, Spalletta G. Updated meta-analyses reveal thalamus volume reduction in patients with first-episode and chronic schizophrenia. Schizophrenia Research. 2010; 123: 1-14.

18.Kemether EM, Buchsbaum MS, Byne W, Hazlett EA, Haznedar M, Brickman AM, Platholi J, Bloom R. Magnetic resonance imaging of mediodorsal, pulvinar, and centromedian nuclei of the thalamus in patients schizophrenia. Archives of General Psychiatry. 2003; 60: 983-91.

19.Janssen J, Aleman-Gomez Y, Reig S, Schnack HG, Parellada M, Graell M, Moreno C, Moreno D, Mateos-Perez JM, Udias JM, Arango C, Desco M. Regional specificity of thalamic volume deficits in male adolescents with early onset psychosis. The British Journal of Psychiatry. 2012; 200; 30-6.

20.Gaser C, Nenadic I, Buchsbaum BR, Hazlett EA, Buchsbaum MS. Ventricular enlargement in schizophrenia related to volume reduction of the thalamus, striatum, and superior temporal cortex. American Journal of Psychiatry. 2004; 161: 154-6.

21.Hallahan B, Newell J, Soares JC, Brambilla P, Strakowski SM, Fleck DE, Kieseppa T, Altshuler LL, Fornito A, Malhi G, McIntosh AM, Yurgelun-Todd DA, Laba KS, Sharma V, MacQueen GM, Murray RM, McDonald C. Structural magnetic resonance imaging in bipolar disorder: an international collaborative mega-analysis of individual adult patient data. Biological Psychiatry. 2001; 69: 326-35.

22.Du MY, Wu QZ, Yue Q, Du MY, Wu QZ, Yue Q, Li J, Liao Y, Kuang WH, Huang XQ, Chan RC, Mechelli A, Gong QY. Voxelwise meta-analysis of gray matter reduction in major depressive disorder. Progress in Neuro-Psychopharmacology Biological Psychiatry. 2012; 36: 11-6..

23.Gilbert AR, Moore GJ, Keshavan MS, Paulson LA, Narula V, MacMaster FP, Stewart CM, Rosenberg DR. Decrease in thalamic volumes of paediatric patients with obsessive-compulsive disorder who are taking paroxetine. Archives of General Psychiatry. 2000; 57: 449-56.

24.Atmaca M, Yildirim H, Ozdemir H, Tezcan E, Poyraz AK. Volumetric MRI study of key brain regions implicated in obsessive-compulsive disorder. Progress in Neuro-psychopharmacology and Biological Psychiatry. 2007; 31: 46-52.

25.Radua J, van den Heuvel OA, Surguladze S, Mataix-Coles D. Meta-analytical comparison of voxel-based morphometry studies in obsessive-compulsive disorder vs other anxiety disorders. Archives of General Psychiatry. 2010; 67: 701-11.

26.de Jong LW, van der Hiele K, Veer IM, Houwing JJ, Westendorp RG, Bollen EL, de Bruin PW, Middlekoop HA, van Buchem MA, van der Grond J. Strongly reduced volumes of putamen and thalamus in Alzheimer's disease: an MRI study. Brain 2008; 131: 3277-85.

27.Seeley WW, Crawford RK, Zhou J, Miller BL, Greicius MD. Neurodegenerative diseases target large-scale human brain networks. Neuron. 2009; 62: 42-52.

28.Looi JCL, Tatham V, Kumar R, Maller JJ, Millard E, Wen W, Chen X, Brodaty H, Sachdev PS. Caudate nucleus volumes in stroke and vascular dementia. Psychiatry Research: Neuroimaging. 2009; 174: 67-75.

29.Zhou J, Gennatas ED, Kramer JH, Miller BL, Seeley WW. Predicting regional neurodegeneration from the healthy brain functional connectome. Neuron. 2012; 73: 1216-27.

30.Ryan NS, Keihaninejad S, Shakespeare TJ, Lehmann M, Crutch SJ, Malone IB, Thornton JS, Mancini L, Hyare H, Yousry T, Ridgway GR, Zhang H, Modat M, Alexander DC, Rossor MN, Ourselin S, Fox NC. Magnetic resonance imaging evidence for presymptomatic change in thalamus and caudate in familial Alzheimer's disease. Brain. 2013; 136: 1399-414.

31.Cordato NJ, Duggins AJ, Halliday GM, Morris JG, Pantelis C. Clinical deficits correlate with regional cerebral atrophy in progressive supranuclear palsy. Brain. 2005; 128: 1259-66.

32.Boxer AL, Geschwind MD, Belfor N,Gorno-Tempini ML, Schauer GF, Miller BL, Weiner MW, Rosen HJ. Patterns of brain atrophy that differentiate corticobasal degeneration syndrome from progressive supranuclear palsy. Archives of Neurology. 2006; 63(1):81-6.

33.Watson R, Blamire AM, O’Brien JT. Magnetic resonance imaging in Lewy Body Dementias. Dementia and Geriatric Cognitive Disorders.209; 28: 493-506.

34.Messina D, Cerasa A, Condino F, Arabia G, Novellino F, Nicoletti G, Salsone M, Morelli M, Lanza PL, Quattroni A. Patterns of brain atrophy in Parkinson’s disease, progressive supranuclear palsy and multiple system atrophy. Parkinsonism Related Disorders. 2011; 17: 172-6.

35.Whitwell JL, Avula R, Master A, Vemuri P, Senjem ML, Jones DT, Jack CR, Josephs KA. Disrupted thalamocortical connectivity in PSP: a resting state fMRI, DTI, VBM study. Parkinsonism and Related Disorders. 2011; 17: 599-605.

36.Padovani A, Borroni B, Brambati SM, Agosti C, Broli M, Alonso R, Scifo P, Bellelli G, Alberici A, Gasparotti R, Perani D. Diffusion tensor imaging and voxel based morphometry study in early progressive supranuclear palsy. Journal of Neurology, Neurosurgery and Psychiatry. 2006; 77: 457-63.

37.Chow TW, Izenberg A, Binns MA, Freedman M, Stuss DT, Ramirez J, Black SE. Magnetic resonance imaging in frontotemporal dementia shows subcortical atrophy. Dementia and Geriatric Cognitive Disorders. 2008; 26: 79-88.

38.Kassubek J, Juengling FD, Ecker D, Landwehrmeyer GB. Thalamic atrophy in Huntington's Disease co-varies with cognitive performance: a morphometric MRI analysis. Cerebral Cortex. 2005; 15: 846-53.

Licensee to OAPL (UK) 2014. Creative Commons Attribution License (CC-BY)

Classification, connections and functions of the dorsal thalamic nuclei of mammals Adapted from: Jones EG (2007) The Thalamus, 2nd edition. Cambridge: Cambridge University Press (Table 3.1); and Kandel ER, Schwartz JH, and Jessell TM (1991) Principles of Neural Science. 3rd ed., Prentice Hall, Sydney. (Table 20-1). 

Voip-info.org started in Sept. 2003. All product names, trademarks and registered trademarks are property of their respective owners. All company, product and service names used in this website are for identification purposes only, and do not imply endorsement.
© 2003-2018 VOIP-Info.org LLC